通过双重方法探索PCSK9对脂蛋白的遗传影响:关联和门德尔随机化
Ya-Ching Chang1, Lung-An Hsu2, Yu-Lin Ko3
1Department of Dermatology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Tao-Yuan 33305, Taiwan.
International journal of molecular sciences
|October 14, 2023
概括
PCSK9 E670G基因变异与较低的脂蛋白 (Lp) 水平有关. 门德尔随机化证实PCSK9水平和Lp (a) 度之间的因果关系,影响心血管风险.
科学领域:
- 遗传学 遗传学 是一个
- 心血管科学 心血管科学
- 生物化学 生物化学
背景情况:
- 之前的研究表明PCSK9 E670G多态性,血PCSK9水平和脂蛋白 (Lp) 度之间存在关联.
- 血PCSK9和Lp(a) 水平之间的因果关系仍然不确定,需要进一步调查.
研究的目的:
- 探索PCSK9 E670G多态和台湾队列中的Lp (a) 水平之间的关联.
- 通过使用孟德尔随机化来确定血PCSK9度和Lp(a) 度之间的因果关系.
主要方法:
- 对614名健康的台湾人进行了一项研究,以检查PCSK9 E670G多态和Lp (a) 水平.
- 采用GWAS和英国生物库总结统计数据对PCSK9和Lp (a) 进行双样本孟德尔随机化分析.
- 六种PCSK9 GWAS相关变异被用作仪器变量来预测血PCSK9水平.
主要成果:
- 独立地,E670G G等位基因与升高Lp (a) 水平的可能性降低有关.
- 在调整心血管风险因素和脂质配置文件后,这种关联仍然显著.
- 门德尔随机化提供了强有力的证据,证明了血PCSK9度和Lp (a) 度之间存在因果关系.
结论:
- 这项研究复制了PCSK9 E670G多态和Lp (a) 水平之间的关联.
- 通过孟德尔随机分析证实了PCSK9水平和Lp(a) 度之间的因果关系.
- 这些发现有助于理解Lp (a) 调节的遗传和因果基础.
相关概念视频
Coronary Artery Disease I: Introduction
17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
Single Nucleotide Polymorphisms-SNPs
15.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.2K
Genome-wide Association Studies-GWAS
13.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.5K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
678
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
678
Coronary Artery Disease IV: Preventive Measures
23
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
23
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
56
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
56


